Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry

Clinical Chemistry

Volumn 59, Issue 3, 2013, Pages 547-556

  Gold, Henrik ^a   Mirzaian, Mina ^a   Dekker, Nick ^a   Ferraz, Maria Joao ^b   Lugtenburg, Johan ^a,b   Codée, Jeroen D C ^a   Van Der Marel, Gijs A ^b   Overkleeft, Herman S ^b   Linthorst, Gabor E ^b   Groener, Johanna E M ^b   Aerts, Johannes M ^a,b   Poorthuis, Ben J H M ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CARBON 13; GLOBOTRIAOSYLSPHINGOSINE; SPHINGOSINE; STABLE ISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; CALIBRATION; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FABRY DISEASE; FEMALE; HUMAN; LIMIT OF QUANTITATION; MALE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REPRODUCIBILITY; STANDARD; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; CALIBRATION; CARBON ISOTOPES; CHROMATOGRAPHY, LIQUID; FABRY DISEASE; GLYCOLIPIDS; HUMANS; ISOTOPE LABELING; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SPHINGOLIPIDS; TANDEM MASS SPECTROMETRY;

EID: 84874618709     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.192138     Document Type: Article

References (16)

1. Desnick R, Ioannou Y, Eng C. a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Sly WA, Beaudet AL, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p 3733-74.
2. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2007;2:e598.
3. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007; 30:68-78.
4. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Babey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 2006;4:289-97.
5. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008;105:2812-7.
6. Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, et al. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 2010;100:257-61.
7. Togawa T, Kawashima I, Kodama T, Tsukimura T, Suzuki T, Fukushige T, et al. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochem Biophys Res Commun 2010;399:716-20.
8. Auray-Blais C, Ntwari A, Clarke JT, Warnock DG, Oliveira JP, Young SP, et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta 2010;411:1906-14.
9. Kruger R, Tholey A, Jakoby T, Vogelsberger R, Mönnikes R, Rossmann H, et al. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;1:883-4.
10. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 2010;1802:741-8.
11. van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 2010;1812:70-6.
12. Gold H, Boot RG, Aerts JMFG, Overkleeft HS, Codé e JDC, van der Marel GA. A concise synthesis of globotriaosylsphingosine. Eur J Org Chem 2011;9:1652-63.
13. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-7.
14. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assesssment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75: 3019-30.
15. Pruett ST, Bushnev A, Hagedorn K, Adiga M, Haynes CA, Sullards MC, et al. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. J Lipid Res 2008;49:1621-39.
16. Jaffe M. Ueber den Niederschlag welchen Pikrinsäure in normalen Harn erzeugt und uber eine neue reaction des Kreatinins. Z Physiol Chem 1886;10:391-400.